British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update
Author(s) Smith C.H.; Mahil S.; Woolf R.T.; Yiu Z.Z.; Bale T. et al.
Source The British journal of dermatology; Mar 2020
The overall aim of the guideline is to provide up-to-date, evidence-based recommendations on the use of biologic therapies targeting TNF (adalimumab, etanercept, certolizumab pegol, infliximab), IL12/23p40 (ustekinumab), IL17A (ixekizumab, secukinumab), IL17RA (brodalumab) and IL23p19 (guselkumab, risankizumab, tildrakizumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis.Copyright This article is protected by copyright. All rights reserved.
Author(s) Zahedi D.; Moori P.; Ashraf I.; Hafeez I.
Source Breathe; Mar 2020; vol. 16 (no. 1)
Author(s) Chichareon P.; Modolo R.; Kawashima H.; Takahashi K.; Kogame N. et al.
Source JACC: Cardiovascular Interventions; Mar 2020; vol. 13 (no. 5); p. 634-646
Objectives: This study assessed the ability of the dual-antiplatelet therapy (DAPT) score in stratifying ischemic and bleeding risk in a contemporary percutaneous coronary intervention (PCI) population. Background(s): The DAPT score is recommended by guidelines as a tool to stratify ischemic and bleeding risk. Its utility in contemporary PCI is unknown.
The following databases were searched:
EMBASE, MEDLINE, PsycINFO, BNI, CINAHL,
to find ELHT staff publications
Archives - past 2 years
Your Specialty or Professional Group
Membership Terms & Conditions